[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508702":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":44,"locations":53,"responsibleParty":70,"collaborators":73,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":31,"eligibilityCriteria":82,"healthyVolunteers":79,"sex":83,"minAge":84,"maxAge":31,"enrollmentInfo":85,"targetDuration":31,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":55,"whyStopped":31,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University of Miami","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Full dose group","EXPERIMENTAL","Participants in this group will receive the full dose of probenecid for a total of 90 days.",[13],"Drug: Probenecid 500 Milligrams (mg)",{"label":15,"type":10,"description":16,"interventionNames":17},"Half dose group","Participants in this group will receive half the dose of probenecid for a total of 90 days.",[18],"Drug: probenecid 250 Milligrams (mg)",{"label":20,"type":21,"description":22,"interventionNames":23},"Control-placebo group","PLACEBO_COMPARATOR","Participants in this group will receive a placebo dose (No active ingredient) for a total of 90 days.",[24],"Drug: Placebo",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Probenecid 500 Milligrams (mg)","Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"probenecid 250 Milligrams (mg)","Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Placebo","Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.",[20],[41],{"name":42,"affiliation":5,"role":43},"Emad Ibrahim, MD","PRINCIPAL_INVESTIGATOR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":31,"email":49},"Odaro Ugbo, BSc","CONTACT","305-243-1491","oxu32@miami.edu",{"name":51,"role":47,"phone":48,"phoneExt":31,"email":52},"Orrey Padilla","oxp210@med.miami.edu",[54],{"facility":5,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"RECRUITING","Miami","Florida","33136","United States","US",{"type":62,"coordinates":63},"Point",[64,65],-80.19366,25.77427,{"lat":65,"lon":64},[68,69],{"name":51,"role":47,"phone":48,"phoneExt":31,"email":52},{"name":42,"role":43,"phone":31,"phoneExt":31,"email":31},{"type":43,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Emad Ibrahim","Associate Professor",[74],{"name":75,"class":76},"Congressionally Directed Medical Research Programs","FED","100508702","phase-3-improvement-of-reproductive-function-in-men-with-spinal-cord-injury-sci-100508702",false,"NCT05903859","Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n1. Subject has a traumatic spinal cord injury.\n2. Subject is male and is 18 years or older.\n\nExclusion Criteria:\n\n1. Subject has been injured less than 1 year.\n2. The subject is known to be azoospermic.\n3. The subject has an indwelling urethral Foley catheter.\n4. Subject is under the age of 18 years.\n5. Subject has an unstable medical condition including, but not limited to, Crohn's disease, ulcerative colitis, colon cancer or has other conditions deemed to be exclusionary per the Investigator.\n6. Subject is unable to consent or comprehend the procedures and their implications.\n7. Subject has a permanent implanted electrical device, i.e., cardiac pacemaker, phrenic nerve stimulator, spinal cord stimulator, etc.\n8. Any subject for whom the procedure or medication is otherwise contraindicated.\n9. Subject has hypersensitivity to probenecid.\n10. Subject has a history of uric acid kidney stones and\u002For peptic ulcer.\n11. The subject has had a febrile Urinary Tract Infection (UTI) within the 2 months prior to enrollment.\n12. The subject is taking methotrexate, aspirin, other salicylates, or anti-inflammatory medicines.\n13. The subject has a history of Glucose-6-phosphate dehydrogenase (G6PD) deficiency.","MALE","18 Years",{"count":86,"type":87},90,"ESTIMATED","INTERVENTIONAL",[90],"PHASE3","This is a study of infertility which often occurs in men with spinal cord injury. Most men with spinal cord injury have a normal sperm count but abnormally low sperm motility - which means that the sperm does not swim well. This study will determine if a medicine given by mouth will improve sperm motility in men with spinal cord injuries. The medicine is called probenecid.",[93],"Infertility, Male",[95],"Spinal cord injury","2026-02-26",{"date":98,"type":99},"2026-03-02","ACTUAL",{"date":101,"type":99},"2024-01-18",{"date":103,"type":87},"2028-12-31",{"name":5,"class":6},1]